ENTA · Enanta Pharmaceuticals Inc · Executive Compensation
Market Cap
$377.47M
Shares
29.13M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $2,769,548 |
| Scott T. Rottinghaus | Chief Medical Officer | $1,343,212 |
| Yat Sun Or | Chief Scientific Officer | $1,293,790 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $2,695,276 |
| Matthew P. Kowalsky | J.D.\ Chief Legal Officer | $1,473,260 |
| Scott T. Rottinghaus | Chief Medical Officer | $1,257,074 |
| Yat Sun Or | Chief Scientific Officer | $1,222,705 |
| Paul Mellett | Chief Financial and Administrative Officer | $1,136,539 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $7,856,698 |
| Nathaniel S. Gardiner | Chief Legal Officer and | $2,855,081 |
| Brendan Luu | Chief Business Officer | $2,577,672 |
| Yat Sun Or | Chief Scientific Officer | $2,469,600 |
| Paul Mellett | Chief Financial and Administrative Officer | $2,375,714 |
| Scott T. Rottinghaus | Chief Medical Officer | $1,654,724 |
| Matthew P. Kowalsky | J.D.\ Chief Legal Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $7,272,656 |
| Scott T. Rottinghaus | Chief Medical Officer | $4,395,965 |
| Nathaniel S. Gardiner | Chief Legal Officer and | $2,382,727 |
| Brendan Luu | Chief Business Officer | $2,313,568 |
| Yat Sun Or | Chief Scientific Officer | $1,992,111 |
| Paul Mellett | Chief Financial and Administrative Officer | $1,887,570 |
| Matthew P. Kowalsky | J.D.\ Chief Legal Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $5,293,709 |
| Brendan Luu | Chief Business Officer | $2,504,966 |
| Tara L. Kieffer | Senior Vice President, New Product Strategy & Development | $2,042,356 |
| Yat Sun Or | Chief Scientific Officer | $1,992,111 |
| Corporate Secretary | — | $1,897,763 |
| Nathaniel S. Gardiner | Senior Vice President and | $1,897,763 |
| Paul Mellett | Chief Financial and Administrative Officer | $1,887,570 |
| Scott T. Rottinghaus | M.D.\ Senior Vice President and Chief Medical Officer | — |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $5,197,837 |
| Yat Sun Or | Senior Vice President, Research & Development and Chief Scientific Officer | $1,844,801 |
| Nathalie Adda | Senior Vice President, Chief Medical Officer | $1,813,418 |
| General Counsel | — | $1,788,991 |
| Nathaniel S. Gardiner | Senior Vice President and General Counsel | $1,788,991 |
| Paul Mellett | Senior Vice President, Finance & Administration and Chief Financial Officer | $1,781,843 |
| Tara L. Kieffer | Senior Vice President, New Product Strategy & Development | — |
| Scott T. Rottinghaus | M.D.\ Senior Vice President and Chief Medical Officer | — |
| Brendan Luu | Senior Vice President, Business Development | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $4,483,503 |
| Yat Sun Or | Senior Vice President, Research & Development, Chief Scientific Officer | $1,630,814 |
| Paul Mellett | Senior Vice President, Finance & Administration, Chief Financial Officer | $1,531,563 |
| Nathalie Adda | Senior Vice President, Chief Medical Officer | $1,494,622 |
| Nathaniel S. Gardiner | Senior Vice President and General Counsel | $1,370,187 |
| Tara L. Kieffer | Senior Vice President, New Product Strategy & Development | — |
| Brendan Luu | Senior Vice President, Business Development | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $4,464,199 |
| Yat Sun Or | Senior Vice President, Research & Development and Chief Scientific Officer | $1,763,435 |
| Nathalie Adda | Senior Vice President, Chief Medical Officer | $1,758,451 |
| Paul Mellett | Senior Vice President, Finance & Administration and Chief Financial Officer | $1,607,853 |
| Nathaniel S. Gardiner | Senior Vice President and General Counsel | $1,509,516 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Jay R. Luly | President and Chief Executive Officer | $4,281,102 |
| Yat Sun Or | Senior Vice President, Research & Development and Chief Scientific Officer | $1,763,435 |
| Nathalie Adda | Senior Vice President, Chief Medical Officer | $1,758,451 |
| Paul Mellett | Senior Vice President, Finance & Administration and Chief Financial Officer | $1,607,853 |
| Nathaniel S. Gardiner | Senior Vice President and General Counsel | $1,509,516 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kathleen ("Katie") S. Capps | interim principal accounting officer | Appointed | 2025-08-27 |
| Harry R. Trout, III | interim principal financial officer | Appointed | 2025-08-27 |
Key facts
CIK
1177648
CUSIP
29251M106
13F (30d)
40 filings
40 filers
Visit website
Investor relations